Skip Navigation

Nephrology Dialysis Transplantation 2008 23(12):i; doi:10.1093/ndt/gfn628
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


In this issue

The first 10% of the full text of this article appears below.

The approval of biosimilars and biopharmaceuticals by EMEA (the European Medicines Agency) has raised some concerns about the efficacy, stability and safety of these products. A workgroup of the ERA/EDTA council has written a position statement on this issue.

See editorial comment by Covic et al., pages 3731–3737

NGAL is a promising troponin for the early detection and . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?